shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)

    RFA-CA-24-029

    National Institutes of Health

    Opening date 29 Jul 2024, 12:00AM

    Closing date 4 Nov 2024, 12:00AM

    Funding Opportunity Number: RFA-CA-24-029

    Opportunity Category: Discretionary

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research,93.394 -- Cancer Detection and Diagnosis Research,93.395 -- Cancer Treatment Research,93.396 -- Cancer Biology Research,93.399 -- Cancer Control

    Cost Sharing or Matching Requirement: No

    Posted Date: Jul 29, 2024 12:00:00 AM EDT

    Closing Date: Nov 04, 2024 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: For profit organizations other than small businesses,Special district governments,Independent school districts,Native American tribal governments (Federally recognized),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,State governments,Native American tribal organizations (other than Federally recognized tribal governments),Others (see text field entitled "Additional Information on Eligibility" for clarification),Private institutions of higher education,County governments,City or township governments,Public and State controlled institutions of higher education,Public housing authorities/Indian housing authorities

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: The overarching objective of this concept is to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research lab, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept